US Stock MarketDetailed Quotes
CMPX Compass Therapeutics
- 0.820
- -0.060-6.82%
Close Jul 3 13:00 ET
- 0.810
- -0.010-1.21%
Post 16:22 ET
112.82MMarket Cap-2342P/E (TTM)
0.930High0.800Low324.31KVolume0.905Open0.880Pre Close273.33KTurnover0.33%Turnover RatioLossP/E (Static)137.59MShares3.04052wk High0.72P/B80.41MFloat Cap0.80052wk Low--Dividend TTM98.07MShs Float8.800Historical High--Div YieldTTM14.77%Amplitude0.800Historical Low0.842Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Compass Therapeutics Stock Forum
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
• $Livent(LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer(SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB(OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings(BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks(SBUX.US)$ +7.18% (matched estimates wi...
No comment yet